Welcome to the 2026 MASLD ECHO® Series!

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) ECHO®

ECHOing Excellence: MASLD/MASH Made Manageable in Primary Care

 

ECHO Session Schedule:

Please note: All sessions: 7-8 pm ET / 6-7 pm CT / 5-6 pm MT / 4-5 pm PT

January 15th, 2026: Defining and Risk-stratifying MASLD/MASH
Presenter: Arpan Mohanty MD, MSc

January 29th, 2026: Emerging Therapeutic Agents for MASLD
Presenter: Meena B. Bansal, MD, FAASLD

February 12th, 2026: Management of MASLD/MASH in People with Other Cardiovascular Comorbidities
Presenter: Ivania Rizo, MD, DABOM

February 26th, 2026: Managing MASLD/ MASH and Related Co-morbidities: Tips and Tricks from an Obesity Medicine Specialist
Presenter: Holly F. Lofton, MD

 

To register for the Zoom sessions click here


 

Key reasons to attend our four-session webinar series:

  • Be able to better identify the conditions of MASLD or those at risk of developing this condition.
  • Gain understanding of how to implement strategies to improve management of patients with MASLD.
  • Discuss the use of non-invasive tests (NITs) in diagnosis and risk stratification of MASLD/MASH.
  • Access expert specialists in real-time collaborative sessions
  • Participate in a Community of Practice (CoP) in a national setting.
  • Discuss actual patient cases as submitted by you and your co-learners!

 

Target Audience:

This ECHO® series is designed for a primary care audience. It is open to physicians, nurse practitioners (NPs), physician associates (PAs), and nurses who care for people with MASLD/MASH.

 

Learning Objectives:

At the conclusion of this learning activity, participants will be better able to:

  1. Define the conditions of MASLD and MASH and their relationship to cardiometabolic conditions such as obesity and type 2 diabetes.
  2. Integrate available non-invasive tests into clinical practice for the identification, risk-stratification, and monitoring of patients with MASLD/MASH.
  3. Identify emerging treatments for MASLD/MASH and the criteria for patient eligibility.
  4. Outline evidence-based management strategies for individuals with MASLD/MASH, including how available therapies (e.g., GLP-1 RAs) can target multiple disease mechanisms.

 

Grantor Acknowledgement:
This activity is supported by an educational grant from Novo Nordisk Inc.

 

Below are the links for claiming credit after each ECHO session. You can click the links below to learn more about each session’s learning objectives.

Credit Claiming Instructions:

To claim your credit for attending the sessions, follow the instructions below:

  1. Click on the link to the session you attended
  2. Click on TAKE COURSE
  3. Follow the prompts to claim your credit on the following page

 

Questions: If you have any questions about the program, registering or claiming credit please write [email protected] and we will reply as quickly as possible.  

  

 

 

Disclaimer:
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS.  ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE.  TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS.  IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS.  IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.  IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.

© Trustees of Boston University, 2025-2026